Efficacy and safety of S-1 based adjuvant chemoradiotherapy for resected pancreatic ductal adenocarcinoma with high-risk pathological feature: a prospective, single-arm, interventional study
Abstract. Objective:. It remains unclear whether adjuvant chemoradiotherapy (CRT) improves survival outcome of pancreatic ductal adenocarcinoma (PDAC) patients after surgery. This study aimed to investigate the efficacy and safety of tegafur/gimeracil/oteracil (S-1)-based adjuvant concurrent chemor...
Main Authors: | Lili Wu, Yaolin Xu, Zhaochong Zeng, Yixing Chen, Yuhong Zhou, Dansong Wang, Jing Sun, Minzhi Lv, Shisuo Du, Wenhui Lou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2022-03-01
|
Series: | Journal of Pancreatology |
Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000084 |
Similar Items
-
Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy
by: Lili Wu, et al.
Published: (2023-07-01) -
The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma
by: Masaru Matsumura, et al.
Published: (2023-03-01) -
Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
by: James J. Biagi, et al.
Published: (2023-07-01) -
Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma
by: Kai Tai Derek Yeung, et al.
Published: (2024-01-01) -
Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma
by: Sami Shoucair, et al.
Published: (2022-12-01)